Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Posted by Donald Scott on Jan 31st, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00. Following the transaction, the president now directly owns 2,893,138 shares of the company’s stock, valued at approximately $33,068,567.34. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Songjiang Ma also recently made the following trade(s):

On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total value of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total value of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $25,000.00.

Gyre Therapeutics Stock Up 0.1 %

GYRE traded up $0.01 during midday trading on Friday, hitting $11.51. The company’s stock had a trading volume of 41,862 shares, compared to its average volume of 101,694. Gyre Therapeutics, Inc. has a 52-week low of $8.26 and a 52-week high of $26.37. The firm has a 50-day moving average price of $11.09 and a two-hundred day moving average price of $12.56.

Institutional Investors Weigh In On Gyre Therapeutics

A number of institutional investors have recently bought and sold shares of GYRE. FMR LLC purchased a new position in Gyre Therapeutics during the third quarter worth approximately $47,000. Barclays PLC raised its position in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares during the period. Renaissance Technologies LLC acquired a new position in Gyre Therapeutics in the second quarter valued at $166,000. Advantage Alpha Capital Partners LP purchased a new stake in Gyre Therapeutics during the third quarter valued at about $334,000. Finally, State Street Corp increased its stake in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after acquiring an additional 8,412 shares during the last quarter. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.